Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone714-508-6100
Debt
Current Ratio2.26
Quick Ratio1.84
Price-To-Earnings
Sales & Book Value
Annual Sales$53.62 million
Price / Sales4.45
Price / Cash FlowN/A
Price / Book4.26
Profitability
Net Income$-21,810,000.00
Net Margins-31.20%
Return on Assets-23.25%
Miscellaneous
Employees186
OptionableOptionable
Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions
What is Avid Bioservices' stock symbol?
Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."
How often does Avid Bioservices pay dividends? What is the dividend yield for Avid Bioservices?
Avid Bioservices declared a dividend on Wednesday, March 7th. Stockholders of record on Monday, March 19th will be paid a dividend of $0.6563 per share on Monday, April 2nd. The ex-dividend date of this dividend is Friday, March 16th. View Avid Bioservices' Dividend History.
When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?
Shares of Avid Bioservices reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.
How were Avid Bioservices' earnings last quarter?
Avid Bioservices Inc (NASDAQ:CDMO) issued its quarterly earnings results on Monday, December, 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.03. The biopharmaceutical company had revenue of $10.18 million for the quarter, compared to the consensus estimate of $10.75 million. Avid Bioservices had a negative return on equity of 38.67% and a negative net margin of 31.20%. View Avid Bioservices' Earnings History.
When is Avid Bioservices' next earnings date?
What guidance has Avid Bioservices issued on next quarter's earnings?
Avid Bioservices issued an update on its FY 2019 earnings guidance on Monday, December, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $51-55 million, compared to the consensus revenue estimate of $54.3 million.
What price target have analysts set for CDMO?
4 brokers have issued 1-year price objectives for Avid Bioservices' stock. Their predictions range from $4.00 to $11.00. On average, they anticipate Avid Bioservices' share price to reach $8.3333 in the next twelve months. This suggests a possible upside of 95.6% from the stock's current price. View Analyst Price Targets for Avid Bioservices.
What is the consensus analysts' recommendation for Avid Bioservices?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avid Bioservices.
What are Wall Street analysts saying about Avid Bioservices stock?
Here are some recent quotes from research analysts about Avid Bioservices stock:
- 1. According to Zacks Investment Research, "Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It also offer process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. Avid Bioservices Inc., formerly known as Peregrine Pharmaceuticals Inc., is based in TUSTIN, United States. " (1/11/2019)
- 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We maintain our Buy rating with a price target of $11. Our valuation is based on a discounted EBITDA model, which we believe takes into account both the established and anticipated revenue growth of Avid, which is the cornerstone of the company’s business. We assign a 23x multiple on F2023 EBIDTA discounted back at Avid’s WACC of 13%. We believe that Avid deserves a multiple premium compared to recent CDMO deals in North Avid Bioservices, Inc." (12/11/2018)
Has Avid Bioservices been receiving favorable news coverage?
Media stories about CDMO stock have trended positive on Thursday, InfoTrie reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avid Bioservices earned a news impact score of 2.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future.
Who are some of Avid Bioservices' key competitors?
Some companies that are related to Avid Bioservices include Retrophin (RTRX), Tricida (TCDA), Deciphera Pharmaceuticals (DCPH), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Epizyme (EPZM), Lexicon Pharmaceuticals (LXRX), ImmunoGen (IMGN), Athenex (ATNX), Y-mAbs Therapeutics (YMAB), Alder Biopharmaceuticals (ALDR), CytomX Therapeutics (CTMX) and Principia Biopharma (PRNB).
Who are Avid Bioservices' key executives?
Avid Bioservices' management team includes the folowing people:
- Dr. Roger J. Lias, Pres, CEO & Director (Age 58)
- Mr. Mark R. Ziebell, VP, Gen. Counsel & Corp. Sec. (Age 54)
- Mr. Daniel R. Hart, Chief Financial Officer (Age 45)
- Ms. Tracy L. Kinjerski, VP of Bus. Operations
- Mr. Stephen Michael Hedberg, Sr. Director of Fin. & SEC Reporting and Principal Financial & Accounting Officer (Age 43)
Who are Avid Bioservices' major shareholders?
Avid Bioservices' stock is owned by a number of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.03%). Company insiders that own Avid Bioservices stock include Joel Mccomb and Mark R Bamforth. View Institutional Ownership Trends for Avid Bioservices.
Which major investors are buying Avid Bioservices stock?
How do I buy shares of Avid Bioservices?
Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avid Bioservices' stock price today?
One share of CDMO stock can currently be purchased for approximately $4.26.
How big of a company is Avid Bioservices?
Avid Bioservices has a market capitalization of $241.09 million and generates $53.62 million in revenue each year. The biopharmaceutical company earns $-21,810,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Avid Bioservices employs 186 workers across the globe.
What is Avid Bioservices' official website?
How can I contact Avid Bioservices?
Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]
MarketBeat Community Rating for Avid Bioservices (NASDAQ CDMO)
MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
